tumor burden

Summary

Summary: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.

Top Publications

  1. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
  2. ncbi YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Cancer Res 67:8014-21. 2007
  3. pmc Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
    Claire M Edwards
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, TN 37232, USA
    Blood 111:2833-42. 2008
  4. doi Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy
    Zhongxing X Liao
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 76:775-81. 2010
  5. doi Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications
    Mathieu Hatt
    Institut National de la Santé et de la Recherche Médicale U650 Brest, France
    Int J Radiat Oncol Biol Phys 77:301-8. 2010
  6. doi Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases
    Alexander Chi
    Department of Radiation Oncology, The University of Arizona, Tucson, AZ 85724 5081, USA
    Int J Radiat Oncol Biol Phys 81:856-62. 2011
  7. doi Evaluation of the planning target volume in the treatment of head and neck cancer with intensity-modulated radiotherapy: what is the appropriate expansion margin in the setting of daily image guidance?
    Allen M Chen
    Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, California 95817, USA
    Int J Radiat Oncol Biol Phys 81:943-9. 2011
  8. doi RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
    Robert E Miller
    Department of Hematology Oncology Research, Amgen Washington, Seattle, Washington 98119 3105, USA
    Mol Cancer Ther 7:2160-9. 2008
  9. doi Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo
    Zhao Hong Wang
    Department of Hepatobiliary Pancreatic Surgery, the Second Affiliated Hospital of Wenzhou Medical College, No 109, West Xue yuan Road, Wenzhou 325027, P R China
    Int J Oncol 39:1123-31. 2011
  10. doi SmartArc-based volumetric modulated arc therapy for oropharyngeal cancer: a dosimetric comparison with both intensity-modulated radiation therapy and helical tomotherapy
    Stefania Clemente
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, USA
    Int J Radiat Oncol Biol Phys 80:1248-55. 2011

Detail Information

Publications308 found, 100 shown here

  1. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
    ..that circulating MDSC levels correlate with clinical cancer stage, CTX-based chemotherapy, and metastatic tumor burden. Whole blood was collected from 106 newly diagnosed solid tumor patients (stages I-IV)...
  2. ncbi YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Cancer Res 67:8014-21. 2007
    ..Further extensive investigation of YM155 in many types of cancer, including HRPC, seems to be worthwhile to develop this novel therapeutic approach...
  3. pmc Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
    Claire M Edwards
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, TN 37232, USA
    Blood 111:2833-42. 2008
    ..chloride (LiCl) treatment activated Wnt signaling in osteoblasts, inhibited myeloma bone disease, and decreased tumor burden in bone, but increased tumor growth when 5TGM1 cells were inoculated subcutaneously...
  4. doi Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy
    Zhongxing X Liao
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 76:775-81. 2010
    ..This retrospective study compares disease outcomes and toxicity in patients treated with concomitant chemotherapy and either 4DCT/IMRT or 3DCRT...
  5. doi Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications
    Mathieu Hatt
    Institut National de la Santé et de la Recherche Médicale U650 Brest, France
    Int J Radiat Oncol Biol Phys 77:301-8. 2010
    ..In addition, the definition of variable uptake regions within the tumor itself may facilitate dose painting for dosimetry optimization...
  6. doi Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases
    Alexander Chi
    Department of Radiation Oncology, The University of Arizona, Tucson, AZ 85724 5081, USA
    Int J Radiat Oncol Biol Phys 81:856-62. 2011
    ..To investigate the ability of helical tomotherapy (HT) to spare critical organs immediately adjacent to the tumor target in stereotactic body radiation therapy (SBRT) for centrally located lung lesions...
  7. doi Evaluation of the planning target volume in the treatment of head and neck cancer with intensity-modulated radiotherapy: what is the appropriate expansion margin in the setting of daily image guidance?
    Allen M Chen
    Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, California 95817, USA
    Int J Radiat Oncol Biol Phys 81:943-9. 2011
    ....
  8. doi RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
    Robert E Miller
    Department of Hematology Oncology Research, Amgen Washington, Seattle, Washington 98119 3105, USA
    Mol Cancer Ther 7:2160-9. 2008
    ..directly prevents osteolysis via blockade of osteoclastogenesis and indirectly reduces progression of skeletal tumor burden by reducing local growth factor and calcium concentrations...
  9. doi Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo
    Zhao Hong Wang
    Department of Hepatobiliary Pancreatic Surgery, the Second Affiliated Hospital of Wenzhou Medical College, No 109, West Xue yuan Road, Wenzhou 325027, P R China
    Int J Oncol 39:1123-31. 2011
    ..This study suggests that emodin enhances the antitumor effect of gemcitabine in SW1990 pancreatic cancer in vitro and in vivo, which may be via the downregulation of NF-κB expression, thus inhibiting the expression of XIAP...
  10. doi SmartArc-based volumetric modulated arc therapy for oropharyngeal cancer: a dosimetric comparison with both intensity-modulated radiation therapy and helical tomotherapy
    Stefania Clemente
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, USA
    Int J Radiat Oncol Biol Phys 80:1248-55. 2011
    ..To investigate the roles of volumetric modulated arc therapy with SmartArc (VMAT-S), intensity-modulated radiation therapy (IMRT), and helical tomotherapy (HT) for oropharyngeal cancer using a simultaneous integrated boost (SIB) approach...
  11. doi Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer
    Yukinori Matsuo
    Department of Radiation Oncology and Image Applied Therapy, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
    Int J Radiat Oncol Biol Phys 79:1104-11. 2011
    ..To investigate the factors that influence clinical outcomes after stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC)...
  12. pmc Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model
    Kai Wen Huang
    Hepatitis Research Center, Department of Surgery, National Taiwan University Hospital, Taipei 100, Taiwan
    Proc Natl Acad Sci U S A 107:14769-74. 2010
    ..Our study implies that in the future, the combination therapy may prove effective for the treatment of patients with advanced HCC...
  13. doi Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway
    Domenico Ribatti
    Dipartimento di Anatomia umana e Istologia, Universita degli Studi di Bari, Italy
    Cancer Treat Rev 37:344-52. 2011
    ..It would appear that the future of angiogenic inhibitors lies in the intelligent combination of multiple targeted agents with other angiogenic inhibitors, as well as more conventional therapies to maximise therapeutic effect...
  14. doi Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
    Shengri Liao
    Department of Radiology, University of Chicago, Chicago, IL 60637, USA
    Eur J Nucl Med Mol Imaging 39:27-38. 2012
    The objective of this study was to assess the prognostic value of metabolic tumor burden on 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) positron emission tomography (PET)/CT measured with metabolic tumor volume (MTV) and total lesion ..
  15. doi Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients
    Mojgan Taremi
    Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 82:967-73. 2012
    ..To present the results of stereotactic body radiotherapy (SBRT) for medically inoperable patients with Stage I non-small-cell lung cancer (NSCLC) and contrast outcomes in patients with and without a pathologic diagnosis...
  16. pmc Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden
    L Connelly
    Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232 6838, USA
    Oncogene 30:1402-12. 2011
    ..We observed an increase in tumor latency and a decrease in final tumor burden in DNMP mice compared with PyVT controls...
  17. ncbi Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma
    Kui Hin Liau
    Hepatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1948-55. 2005
    ..Surgical resection for large (> 10 cm) hepatocellular carcinoma (HCC) is believed by many to be ineffective. The objective of the current study was to review the outcome of partial hepatectomy in patients with large HCC...
  18. pmc Complementarity of ultrasound and fluorescence imaging in an orthotopic mouse model of pancreatic cancer
    Cynthia S Snyder
    Moores UCSD Cancer Center, University of California, La Jolla, CA, USA
    BMC Cancer 9:106. 2009
    ..goal, we performed whole-body fluorescence imaging and ultrasound imaging to evaluate and to compare these noninvasive imaging modalities for assessing tumor burden and tumor progression in an orthotopic mouse model of pancreatic cancer.
  19. ncbi Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden
    Zain Paroo
    The University of Texas Southwestern Medical Center at Dallas, 75390 9058, USA
    Mol Imaging 3:117-24. 2004
    ..shows that despite the dynamic and variable nature of bioluminescence, where appropriate experimental precautions are taken, single time point BLI may be useful for noninvasive, high-throughput, quantitative assessment of tumor burden.
  20. ncbi Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage
    Satoru Oshino
    Department of Neurosurgery, Osaka University Graduate School of Medicine, Japan
    Endocr J 53:125-32. 2006
    ..These results will lead to more effective selection of patients for preoperative octreotide treatment...
  21. pmc Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes
    Gisela Weskamp
    Arthritis and Tissue Degeneration Program, Caspary Research Building, Room 426, Hospital for Special Surgery, 535 E 70th St, New York, NY 10021, USA
    Circ Res 106:932-40. 2010
    ..These findings raised interesting questions about the role of ADAM17 in angiogenesis and neovascularization in vivo...
  22. doi Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix
    Daniel Zwahlen
    Radiation Medicine Program, Princess Margaret Hospital Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 74:1157-64. 2009
    ..To determine the feasibility and benefits of optimized magnetic resonance imaging (MRI)-guided brachytherapy (BT) for cancer of the cervix...
  23. pmc Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer
    Trang H La
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Int J Radiat Oncol Biol Phys 74:1335-41. 2009
    ....
  24. doi IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer
    Asa Andersson
    Department of Medicine, University of California Los Angeles Lung Cancer Research Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 182:6951-8. 2009
    ..IL-7 decreased tumor burden with concomitant increases in the frequency of CD4 and CD8 T lymphocyte subsets, T cell activation markers ..
  25. pmc PI3Kα inhibitors that inhibit metastasis
    Oleg Schmidt-Kittler
    The Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Oncotarget 1:339-48. 2010
    ..These data support the idea that PI3Kα plays an important role in the metastatic process and suggest a more informed strategy for selecting drugs worthy of further development for clinical application...
  26. doi Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy
    Frank J Lagerwaard
    Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 75:253-9. 2009
    ..We used RA to plan and deliver whole-brain radiotherapy (WBRT) with a simultaneous integrated boost in patients with multiple brain metastases...
  27. doi Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis
    Ling Zhi Liu
    Department of Pathology, Lab of Reproductive Medicine, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu, China
    Cancer Res 68:8183-8. 2008
    ..This study helps to understand the role and molecular mechanism of p70S6K1 in regulating angiogenesis and tumor growth, and the role of endothelial p70S6K1/HIF-1 signaling in the regulation of tumor microenvironment and angiogenesis...
  28. pmc Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
    Victor F Mautner
    Department of Maxillofacial Surgery, University Hospital Eppendorf, Hamburg, Germany
    Neuro Oncol 10:593-8. 2008
    ..Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop...
  29. doi A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data
    Andrea Schaefer
    Department of Nuclear Medicine, Saarland University Medical Center, 66421, Homburg, Germany
    Eur J Nucl Med Mol Imaging 35:1989-99. 2008
    ..An easily applicable algorithm for the FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer was developed by phantom measurements and validated in patient data...
  30. doi Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
    Alejandro Forner
    Liver Unit, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, August Pi i Sunyer Institute of Biomedical Investigations, Biomedical Center for Research into Hepatic and Digestive Diseases CIBEREHD, University of Barcelona, Barcelona, Spain
    Cancer 115:616-23. 2009
    ..EASL) guidelines recommended that assessment of tumor response should incorporate the reduction in viable tumor burden. The current report provides an assessment of the agreement/concordance between both RECIST and the EASL ..
  31. doi Dosimetric impact of online correction via cone-beam CT-based image guidance for stereotactic lung radiotherapy
    Ana Paula Galerani
    Department of Radiation Oncology, Clinirad, Angelina Caron Hospital, Curitiba, Parana, Brazil
    Int J Radiat Oncol Biol Phys 78:1571-8. 2010
    ..To evaluate the dosimetric impact of online cone-beam computed tomography (CBCT) guided correction in lung stereotactic body radiation therapy (SBRT)...
  32. doi Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer
    James Stewart
    Princess Margaret Hospital Ontario Cancer Institute, University Health Network, Toronto, Canada
    Int J Radiat Oncol Biol Phys 78:350-8. 2010
    ..In addition, the dosimetric consequences of organ and tumor motion are modeled using a combination of deformable registration and fractional dose accumulation techniques...
  33. pmc DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma
    Stefanie Galban
    Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS ONE 7:e35857. 2012
    ..DW-MRI provided early changes to radiosensitization treatment warranting evaluation of this imaging biomarker in clinical trials...
  34. doi Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma
    Hyung Jun Im
    Department of Nuclear Medicine, National Cancer Center, Goyang si, Gyeonggi Do, Korea
    Eur J Nucl Med Mol Imaging 39:39-49. 2012
    ..Furthermore, little is known of the early PET/CT responses after only one chemotherapy course...
  35. ncbi Metabolic tumor burden predicts for disease progression and death in lung cancer
    Percy Lee
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305 5847, USA
    Int J Radiat Oncol Biol Phys 69:328-33. 2007
    ..However, stage may be simply a surrogate for underlying tumor burden. Our purpose was to assess the prognostic value of tumor burden measured by 18F-fluorodeoxyglucose-positron ..
  36. doi Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer
    Xue Meng
    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, China
    Int J Radiat Oncol Biol Phys 82:960-6. 2012
    ....
  37. doi Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology
    Mathieu Hatt
    INSERM, U650 LaTIM, CHU Morvan, 5 avenue Foch, 29609 Brest, France
    Eur J Nucl Med Mol Imaging 38:1191-202. 2011
    ..The objectives of this work were to investigate the prognostic value of these indices in oesophageal cancer patients undergoing combined chemoradiotherapy treatment and the impact of TV delineation strategies...
  38. pmc p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner
    Yoseph Addadi
    Department of Biological Regulation, The Weizmann Institute, Rehovot, Israel
    Cancer Res 70:9650-8. 2010
    ..Moreover, expression of mutant p53 by tumor stroma fibroblasts might exert a gain of function effect, further accelerating tumor development...
  39. doi Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases
    Nicholas F Marko
    Department of Neurosurgery, The Cleveland Clinic, Cleveland, OH 44195, USA
    World Neurosurg 73:186-93; discussion e29. 2010
    ....
  40. pmc Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts
    Wei Meng Zhao
    Galaxy Biotech, LLC, Sunnyvale, California 94089, USA
    Clin Cancer Res 16:5750-8. 2010
    ..We investigated whether monoclonal antibodies (mAbs) directed against FGFR2 can inhibit the growth of tumors in xenograft models...
  41. doi Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma
    Peng Yuan Zhuang
    Department of General Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People s Republic of China
    J Cancer Res Clin Oncol 136:1891-900. 2010
    ..To elucidate the effect of IFN-α treatment on tumor growth and metastasis of hepatocellular carcinoma (HCC)...
  42. doi Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma
    Shahab Uddin
    Department of Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
    Endocr Relat Cancer 17:191-202. 2010
    ..Altogether, these data show that leptin plays an important role in PTC pathogenesis through PI3K/AKT pathway via Ob-R and is a potential prognostic marker associated with an aggressive phenotype and poor disease-free survival...
  43. doi Oral administration of resveratrol in suppression of pulmonary metastasis of BALB/c mice challenged with CT26 colorectal adenocarcinoma cells
    Ya Ling Weng
    Department of Food Science, National Chiayi University, Chaiyi, Taiwan
    Mol Nutr Food Res 54:259-67. 2010
    ..Tumor lumps or nodules were not detected at the injection sites or in the lungs. This reveals that intrinsic vaccination-like defense has resulted from administration of resveratrol and challenge of tumor cells...
  44. doi Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma
    Stephanie J Gros
    Department of General, Visceral, and Thoracic Surgery, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Mol Cancer Ther 9:2037-45. 2010
    ..Treatment of this highly treatment-resistant disease with trastuzumab in the adjuvant setting to prevent lymph node metastasis after primary tumor resection is suggested by the data in this report...
  45. doi SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo
    Shuang Zhang
    State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, People s Republic of China
    Clin Cancer Res 17:4439-50. 2011
    ..However, currently most of these anticancer drugs suffer some adverse effects. Discovery of novel VEGFR2 inhibitors as anticancer drug candidates is still needed...
  46. ncbi Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis
    Pamela M Holland
    Department of Oncology, Amgen Inc, Seattle, WA 98119, USA
    Cancer Biol Ther 9:539-50. 2010
    ..of RANKL in models of breast cancer bone metastases blocks tumor-induced osteolysis and reduces skeletal tumor burden.  In addition, the skeleton is co-opted by tumor cells and functions as a supportive tumor microenvironment...
  47. pmc An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis
    Marion Zillhardt
    Department of Obstetrics, University of Chicago, Chicago, IL 60637, USA
    Neoplasia 12:1-10. 2010
    ..study was to determine whether blocking c-Met with an orally available c-Met inhibitor, PF-2341066, reduces tumor burden and increases survival in a xenograft model of ovarian cancer metastasis...
  48. doi The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy
    Seza A Gulec
    Florida International University College of Medicine, Jackson North Medical Center, 100 NW 170th Street Suite 410, North Miami Beach, FL 33169, USA
    Eur J Nucl Med Mol Imaging 38:1289-95. 2011
    ....
  49. doi Early treatment response evaluation in patients with diffuse large B-cell lymphoma--a pilot study comparing volumetric MRI and PET/CT
    Xingchen Wu
    Department of Oncology, Tampere University Hospital, Tampere, Finland
    Mol Imaging Biol 13:785-92. 2011
    ....
  50. doi A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy
    R Bryan Barriger
    Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Int J Radiat Oncol Biol Phys 82:457-62. 2012
    ..To examine the rates and risk factors of radiation pneumonitis (RP) in non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT)...
  51. pmc Partial volume correction strategies for quantitative FDG PET in oncology
    Nikie J Hoetjes
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:1679-87. 2010
    ..The purpose of the present study was to assess accuracy and precision of different partial volume correction (PVC) methods...
  52. doi Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
    Gherardo Mazziotti
    Department of Medical and Surgical Sciences, University of Brescia, c o Endocrinology Service, Montichiari Hospital, Via Ciotti 154, 25018, Montichiari, Italy
    Pituitary 13:60-7. 2010
    ..This finding suggests that this drug may have a role in the primary treatment of acromegaly...
  53. doi Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study
    Zhi Gang Ren
    Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai, China, 200032
    Int J Radiat Oncol Biol Phys 79:496-502. 2011
    ....
  54. doi Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification
    Sheng Chieh Chan
    Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan
    Nucl Med Commun 32:989-96. 2011
    ..To investigate the prognostic impact of different 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (¹⁸F-FDG PET) parameters in patients with advanced nasopharyngeal carcinoma (NPC)...
  55. doi The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models
    Georgios Iliadis
    Department of Radiation Oncology, Papageorgiou General Hospital, Thessaloniki, Greece
    Strahlenther Onkol 185:743-50. 2009
    ....
  56. ncbi A novel iterative method for lesion delineation and volumetric quantification with FDG PET
    Jorn A van Dalen
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, The Netherlands
    Nucl Med Commun 28:485-93. 2007
    ..A novel, model-based method is hypothesized to provide threshold levels independent f the SBR and to allow accurate measurement of volumes down to the resolution of the PET scanner...
  57. doi Tumor burden of sentinel lymph node metastasis in Merkel cell carcinoma
    Virve Koljonen
    Department of Plastic Surgery, Helsinki University Hospital, Toolo Hospital, Helsinki, Finland
    J Cutan Pathol 38:508-13. 2011
    ..However, the concept of tumor burden with respect to MCC involving sentinel lymph nodes has not been analyzed...
  58. pmc Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer
    Terry Hyslop
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Clin Cancer Res 17:3293-303. 2011
    ..Here, we defined the association of occult tumor burden, quantified by GUCY2C reverse transcriptase-PCR (RT-PCR), with outcomes in colorectal cancer.
  59. doi Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor
    Daniel J Freeman
    Department of Oncology Research, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Mol Cancer Ther 8:1536-46. 2009
    ....
  60. doi Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics
    Diana Narita
    Department of Biochemistry, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania
    Acta Histochem 114:131-9. 2012
    ..High-grade cancers showed significantly increased expression of ADAM17. Our study on laser-capture microdissected specimens confers motivation for future work on development of ADAM-selective inhibitors for treatment of breast cancers...
  61. doi PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings?
    Kailiang Wu
    Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 77:699-706. 2010
    ..In this present study, different PET CT threshold values were used for target delineation and then compared pathologically...
  62. pmc A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models
    Yanlan Yu
    Department of Urology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, People s Republic of China
    PLoS ONE 5:e9072. 2010
    ..These studies provide proof of principle for the feasibility of developing humanized RabMAbs as therapeutics...
  63. doi Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model
    Ya Jen Chang
    Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC
    Nucl Med Biol 37:95-104. 2010
    ....
  64. pmc Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes
    Terry Hyslop
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer 118:2532-40. 2012
    ..Recurrence in pN0 patients suggests the presence of occult metastases undetected by conventional approaches. This study explores the association of racial differences in outcomes with occult tumor burden in regional lymph nodes.
  65. ncbi Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations
    Veselina Goranova-Marinova
    Clinic of Hematology, University Hospital Sv Georgi Plovdiv, Plovdiv, Bulgaria
    Haematologica 92:1000-1. 2007
    ..Renal failure modified the expression of OPG. RANKL and RANKL/OPG ratios are informative markers for myeloma tumor burden and MBD.
  66. pmc Tumor growth instability and its implications for chemotherapy
    Paolo Castorina
    Dipartimento di Fisica, Universita di Catania, Istituto Nazionale Fisica Nucleare Catania, and Centro Siciliano Fisica Nucleare e Struttura della Materia, Catania, Italy
    Cancer Res 69:8507-15. 2009
    ..Both cases point toward testable potential refinements of the Norton-Simon late intensity schedule...
  67. ncbi Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma
    Ihab R Kamel
    Russell H Morgan Department of Radiology and Radiological Sciences, Division of Vascular and Interventional Radiology, Baltimore, MD 21287, USA
    J Vasc Interv Radiol 18:49-56. 2007
    ....
  68. ncbi Lung cancer: computerized quantification of tumor response--initial results
    Binsheng Zhao
    Department of Medical Physics and Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 241:892-8. 2006
    ..To prospectively quantify tumor response or progression in patients with lung cancer by using thin-section computed tomography (CT) and a semiautomated algorithm to calculate tumor volume and other parameter values...
  69. pmc Non-invasive detection of a small number of bioluminescent cancer cells in vivo
    Jae Beom Kim
    Caliper Life Sciences Inc, Alameda, California, United States of America
    PLoS ONE 5:e9364. 2010
    ..Significantly higher luciferase activity in these cells allowed us to detect micrometastases in both, syngeneic Balb/c and nu/nu mice...
  70. doi In vivo micro-CT imaging of rat brain glioma: a comparison with 3T MRI and histology
    Tobias Engelhorn
    Department of Neuroradiology, University of Erlangen Nuremberg, Schwabachanlage 6, D 91054 Erlangen, Germany
    Neurosci Lett 458:28-31. 2009
    ..14). In conclusion, micro-CT allows in vivo imaging of the contrast-enhancing part of experimental gliomas with an accuracy comparable to high-field MRI...
  71. pmc Head and neck cancer: how imaging predicts treatment outcome
    Robert Hermans
    Department of Radiology, University Hospitals Leuven, Leuven, Belgium
    Cancer Imaging 6:S145-53. 2006
    ..Early posttreatment imaging studies contain important prognostic information, and allow selection of patients for further treatment or watchful waiting...
  72. doi Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis
    Valerie Panet-Raymond
    Department of Oncology, Division of Radiation Oncology, McGill University, Montreal, QC, Canada
    Int J Radiat Oncol Biol Phys 73:473-8. 2009
    ..In an attempt to improve results, we have begun a program of accelerated hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concomitant and adjuvant temozolomide (TMZ)...
  73. doi Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden
    Elliot L Servais
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Curr Protoc Pharmacol . 2011
    ..Pleural tumor growth in this model resembles the regionally aggressive clinical course and tumor microenvironment of human pleural cancers and provides an optimal animal model to investigate MPD biology and therapies...
  74. doi Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication
    Michael I Koukourakis
    Department of Radiotherapy Oncology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
    Inflammation 32:169-75. 2009
    ..Anti-hypertensive drugs appear as potent suppressors of the tumor-induced CRP production...
  75. pmc Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors
    Brian L Lindshield
    Division of Nutritional Sciences, University of Illinois at Urbana Champaign, Urbana, Illinois, United States of America
    PLoS ONE 5:e10423. 2010
    ..However, it is not clear whether consumption of these compounds, alone or in combination, results in improved outcomes...
  76. doi Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy
    Marc D Piroth
    Department of Radiation Oncology, RWTH Aachen University Hospital, Germany
    Radiother Oncol 99:218-24. 2011
    ..In a prospective study we investigated the prognostic impact of postoperative tumor volume and tumor/brain ratios (TBR) in PET using O-(2-[(18)F]fluoroethyl)-l-tyrosine (FET) in comparison with MRI...
  77. ncbi Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy
    Jason L J Dearling
    Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, University College London, London, UK
    Clin Cancer Res 13:1903-10. 2007
    ..In an attempt to overcome these challenges, radioimmunotherapy was combined with 2-deoxy-d-glucose (2DG), a hypoxia-selective cytotoxic inhibitor of glucose metabolism...
  78. ncbi Defective antitumor responses in CX3CR1-deficient mice
    Yen Rei A Yu
    Thurston Arthritis Research Center and the Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Int J Cancer 121:316-22. 2007
    ..We found that B16-treated CX3CR1-/- mice had increased lung tumor burden and cachexia...
  79. doi Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy
    Young Mi Seol
    Division of Hemato Oncology, Department of Internal Medicine, National University Hospital Medical Research Institute, Seo Gu, Busan, Korea
    Acta Oncol 49:201-8. 2010
    ....
  80. ncbi Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors
    Joep Stroom
    Department of Radiotherapy, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 69:267-75. 2007
    ..In this pilot study, we investigated the feasibility of pathology-correlated imaging for lung tumors, taking into account lung deformations after surgery...
  81. ncbi Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: Implications for conformal dose-escalation studies
    Christina Tsien
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
    Int J Radiat Oncol Biol Phys 62:328-32. 2005
    ..To determine whether changes in tumor volume occur during the course of conformal 3D radiotherapy of high-grade gliomas by use of magnetic resonance imaging (MRI) during treatment and whether these changes had an impact on tumor coverage...
  82. doi Quantitative analysis of tumor growth rate and changes in tumor marker level: specific growth rate versus doubling time
    Esmaeil Mehrara
    Department of Radiation Physics, University of Gothenburg, Goteborg, Sweden
    Acta Oncol 48:591-7. 2009
    ..DT is also used for defining changes in tumor marker level. The aim of this study was to compare DT and SGR as measures of growth rate when the uncertainty is negligible...
  83. doi Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer
    Man Ki Chung
    Departments of Otorhinolaryngology Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Clin Cancer Res 15:5861-8. 2009
    ....
  84. doi Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma
    Cassandra R Diegel
    Laboratory of Cell Signaling and Carcinogenesis, Van Andel Research Institute, Grand Rapids, Michigan 49504, USA
    Cancer Res 70:9143-52. 2010
    ..Because rapamycin analogues are approved for treating other types of human malignancies, our findings suggest that rapamycin therapy should be evaluated for treating patients with salivary gland acinic cell carcinoma...
  85. pmc Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden
    Hector Guillen-Ahlers
    W M Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, United States of America
    PLoS ONE 5:e9070. 2010
    ..Fas, a member of the tumor necrosis family, is responsible for initiating the apoptotic pathway when bound to its ligand, Fas-L. Defects in the Fas-mediated apoptotic pathway have been reported in colorectal cancer...
  86. pmc Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age
    Shawn A Ritchie
    Phenomenome Discoveries Inc, Saskatoon, Saskatchewan, Canada
    BMC Gastroenterol 10:140. 2010
    ..The following studies were carried out to assess whether conventional therapy would result in restoration of systemic hPULCFAs in CRC patients, and to investigate the relationship between hPULCFA levels and age...
  87. doi Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia
    Siranoush Shahrzad
    Department of Biomedical Sciences, University of Guelph, ON, Canada
    Cancer Lett 297:75-83. 2010
    ..Thus DCA is cytoprotective to some CRC cells under hypoxic conditions, highlighting the need for further investigation before DCA can be used as a reliable apoptosis-inducing agent in cancer therapy...
  88. doi Early outcomes of endoscopic transsphenoidal surgery for adult craniopharyngiomas
    John A Jane
    Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia, USA
    Neurosurg Focus 28:E9. 2010
    ..The purpose of this study was to report the outcomes of the endoscopic transsphenoidal approach for adults with craniopharyngiomas in whom the goal was gross-total resection...
  89. ncbi Magnetic resonance spectroscopy suggests key differences in the metastatic behaviour of medulloblastoma
    Andrew C Peet
    Academic Department of Paediatrics and Child Health, University of Birmingham, Whittall Street, Birmingham B4 6NH, UK
    Eur J Cancer 43:1037-44. 2007
    ..Metastatic medulloblastoma has a poorer prognosis than localised disease in part due to inherent properties of the tumour. 1H magnetic resonance spectroscopy (MRS) provides a powerful method for investigating tumour metabolism in vivo...
  90. ncbi Reduce in variation and improve efficiency of target volume delineation by a computer-assisted system using a deformable image registration approach
    K S Clifford Chao
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 7030, USA
    Int J Radiat Oncol Biol Phys 68:1512-21. 2007
    ....
  91. ncbi Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission
    Antonio Rueda
    Oncology Department, Hospital Clinico Universitario, Malaga, Spain
    Clin Lymphoma Myeloma 7:400-5. 2007
    ..Hodgkin lymphoma represents approximately one fifth of all lymphomas, and the roles of angiogenesis and VEGF in Hodgkin lymphoma have not been well defined at present...
  92. ncbi Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer
    H Helen Liu
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:531-40. 2007
    ..To assess three-dimensional tumor motion caused by respiration and internal target volume (ITV) for radiotherapy of lung cancer...
  93. pmc Stereotactic body radiotherapy for lesions of the spine and paraspinal regions
    John W Nelson
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 73:1369-75. 2009
    ..To describe our experience and clinical strategy for stereotactic body radiotherapy (SBRT) of spinal lesions...
  94. doi Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database
    Christian Toso
    Section of Hepatobiliary, Pancreatic, and Transplant Surgery, University of Alberta, Edmonton, Canada
    Hepatology 49:832-8. 2009
    ..A composite patient selection score combining TTV and AFP was the most effective of all tested staging criteria for the prediction of posttransplant patient survival for candidates with HCC...
  95. ncbi Apoptin induces apoptosis in an oral cancer mouse model
    Remilio A L Schoop
    Department of Otolaryngology, Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Cancer Biol Ther 7:1368-73. 2008
    ..The fact that apoptin induces apoptosis in primary squamous cell carcinoma cells indicates that apoptin is a potential therapeutic agent for treatment of head and neck squamous cell carcinoma...
  96. ncbi Partial-volume effect in PET tumor imaging
    Marine Soret
    UMR 678 INSERM UPMC, CHU Pitie Salpetriere, Paris, France
    J Nucl Med 48:932-45. 2007
    ..The parameters on which PVE depends are reviewed. Actions that can be taken to reduce the errors attributable to PVE are described. Various PVE correction schemes are presented, and their applicability to PET tumor imaging is discussed...
  97. doi A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System
    Chia Yang Hsu
    Faculty of Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan
    J Hepatol 53:108-17. 2010
    ..The optimal prognostic model for HCC is still under intense debate. This study aimed to propose a new staging system for HCC based on total tumor volume (TTV) and to compare it with the currently used systems...
  98. doi Image guidance based on prostate position for prostate cancer proton therapy
    Carlos Vargas
    Department of Radiation Oncology, University of Florida Proton Therapy Institute, 2015 N Jefferson Street, Jacksonville, FL 32206, USA
    Int J Radiat Oncol Biol Phys 71:1322-8. 2008
    ..To determine the target coverage for proton therapy with and without image guidance and daily prebeam reorientation...
  99. pmc K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and St Agnes Hospital, Baltimore, Maryland 21231, USA
    Clin Cancer Res 16:338-47. 2010
    ..A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia...
  100. pmc Role of tissue factor in cancer
    Raj S Kasthuri
    Division of Hematology and Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 27:4834-8. 2009
    ..Nevertheless, additional studies are needed to determine if this strategy can be successfully translated to the treatment of cancer patients...
  101. doi Long-term outcome of uterine artery embolization for symptomatic uterine leiomyomas
    Paul N M Lohle
    Department of Radiology, St Elisabeth Ziekenhuis, Tilburg University, Tilburg, The Netherlands
    J Vasc Interv Radiol 19:319-26. 2008
    ..To evaluate long-term outcomes and factors associated with treatment failure after uterine artery embolization (UAE) in women with symptomatic uterine leiomyomas...

Research Grants90

  1. Telomeres, telomerase and chemotherapy: Bench to bedside
    JESSIE AU; Fiscal Year: 2007
    ..support multiple rounds of cell proliferation, so that telomerase inhibition is not cytotoxic before a lethal tumor burden is reached...
  2. Improved Drug Delivery to Tumors Using Novel Tissue Perfusion Approaches
    Lisa Coussens; Fiscal Year: 2009
    ..following Alk5 blockade by monitoring histopathologic characteristics of mammary adenocarcinomas, as well as tumor burden, tumor latency (to endpoint), and frequency of pulmonary metastasis, and further demonstrate that MR imaging ..
  3. Fluorophore-Conjugated Antibodies for Imaging and Resection of GI Tumors
    Meng Yang; Fiscal Year: 2010
    ..monoclonal antibodies against tumor antigen CA19-9 and CEA or a combination of both to evaluate tumor burden in vivo in an orthotopic metastatic nude mouse model of human pancreatic and colon cancer and to facilitate the ..
  4. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2007
    ..target & propagate in myeloma deposits throughout the body leading to tumor cell killing and reduction of tumor burden. Aim 2: To characterize MV-NIS gene expression using 123-I, gamma camera imaging, and SPECT/CT imaging and to ..
  5. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2009
    ..target & propagate in myeloma deposits throughout the body leading to tumor cell killing and reduction of tumor burden. Aim 2: To characterize MV-NIS gene expression using 123-I, gamma camera imaging, and SPECT/CT imaging and to ..
  6. Virotherapy for Relapsed Refractory Multiple Myeloma
    Angela Dispenzieri; Fiscal Year: 2010
    ..target &propagate in myeloma deposits throughout the body leading to tumor cell killing and reduction of tumor burden. Aim 2: To characterize MV-NIS gene expression using 123-I, gamma camera imaging, and SPECT/CT imaging and to ..
  7. Anti-GM1b IgM for Detection of Localized Prostate Cancer
    Mepur Ravindranath; Fiscal Year: 2005
    ....
  8. Gene Therapy for Retinoblastoma
    Richard Hurwitz; Fiscal Year: 2003
    ..The ultimate goal of this gene therapy is to salvage the affected eye by reducing the tumor burden sufficiently to allow for local control of the disease...
  9. Antiretroviral Therapy of AIDS-Related Kaposi's Sarcoma in Africa
    Jeffrey Martin; Fiscal Year: 2009
    ..inhibitor (NNRTI)-based HAART regimen (efavirenz plus zidovudine/lamivudine) in promoting the regression of KS tumor burden in persons with AIDS-related KS in Africa; (2) Evaluate which pre-HAART parameters are predictive of KS ..
  10. Antiretroviral Therapy of AIDS-Related Kaposi's Sarcoma in Africa
    Jeffrey Martin; Fiscal Year: 2007
    ..inhibitor (NNRTI)-based HAART regimen (efavirenz plus zidovudine/lamivudine) in promoting the regression of KS tumor burden in persons with AIDS-related KS in Africa; (2) Evaluate which pre-HAART parameters are predictive of KS ..
  11. In Vivo Flow Cytometry to Measure Circulating Tumor Load
    David Benaron; Fiscal Year: 2004
    ..If successful, this may lead to improved staging, treatment monitoring, and possibly earlier diagnosis. ..
  12. LCDIO FOR LYMPH NODE MR IMAGING
    Ralph Weissleder; Fiscal Year: 2001
    ..For example, recent clinical trials demonstrate that minimal nodal tumor burden in non-enlarged nodes is indeed detectable by LCDIO enhanced MR imaging...
  13. Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
    Rajendra Mehta; Fiscal Year: 2009
    ..that treatment of animals with the active metabolite of vitamin D, 1,25-dihydroxyvitamin D3, reduces colon tumor burden. However, 1,25(OH)2D3 causes hypercalcemia. In view of this numerous analogs of vitamin D have been synthesized...
  14. Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
    Rajendra Mehta; Fiscal Year: 2007
    ..that treatment of animals with the active metabolite of vitamin D, 1,25-dihydroxyvitamin D3, reduces colon tumor burden. However, 1,25(OH)2D3 causes hypercalcemia. In view of this numerous analogs of vitamin D have been synthesized...
  15. Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
    Rajendra G Mehta; Fiscal Year: 2010
    ..that treatment of animals with the active metabolite of vitamin D, 1,25-dihydroxyvitamin D3, reduces colon tumor burden. However, 1,25(OH)2D3 causes hypercalcemia. In view of this numerous analogs of vitamin D have been synthesized...
  16. Chemoprevention of Lung Cancer with Anti-tumor B
    Ming You; Fiscal Year: 2009
    ..Furthermore, the results from this proposal will also provide significant insights on the active inhibitory components and how they affect lung carcinogenesis process. ..
  17. Chemoprevention of Lung Cancer with Anti-tumor B
    Ming You; Fiscal Year: 2010
    ..Furthermore, the results from this proposal will also provide significant insights on the active inhibitory components and how they affect lung carcinogenesis process. ..
  18. Chemoprevention of Lung Cancer with Anti-tumor B
    Ming You; Fiscal Year: 2007
    ..Furthermore, the results from this proposal will also provide significant insights on the active inhibitory components and how they affect lung carcinogenesis process. ..
  19. THERAPY FOR AIDS CENTRAL NERVOUS SYSTEM LYMPHOMA
    Michael Caligiuri; Fiscal Year: 2002
    ..The limitations of the animal model preclude its use for studying the pathogenesis of AIDS PCNSL. ..
  20. DIETARY SOYBEAN COMPONENTS AFFECT ON PROSTATE CANCER PRO
    Jin Rong Zhou; Fiscal Year: 2001
    ..It is expencted that the results from proposed project will be translated to future clinical trials on CaP prevention/intervention. ..
  21. GLOBE CONSERVATION IN TRANSGENIC RETINOBLASTOMA
    Timothy Murray; Fiscal Year: 2006
    ..Pilot data suggests that angiostatic therapy is effective in the reduction of tumor burden in a murine transgenic model of retinoblastoma...
  22. A Phase II Trial for Neutron Capture Therapy in Melanoma
    Paul Busse; Fiscal Year: 2003
    ..These data will be used to refine the predictive accuracy of a two-compartment pharmacokinetic model developed by this research group from human clinical data. ..
  23. PROGESTERONE RECEPTOR IN MYOMETRIUM AND LEIOMYOMA
    Robin Fuchs Young; Fiscal Year: 2002
    ..are often associated with infertility and an additional 18,000 myomectomies are performed each year to reduce tumor burden while sparing the uterus...
  24. Liposome Delivery of Boron for BNCT
    M Hawthorne; Fiscal Year: 2007
    ..The normal tissue response will be quantified in a rat model. The proposed studies will provide the radiobiological data required to decide whether to proceed to large animal or human studies. ..
  25. Telomeres, telomerase and chemotherapy: Bench to bedside
    JESSIE AU; Fiscal Year: 2009
    ..support multiple rounds of cell proliferation, so that telomerase inhibition is not cytotoxic before a lethal tumor burden is reached...
  26. Diversification of Cytotoxic Effector Cells Via LPS-activated DCs
    Anna Karolina Palucka; Fiscal Year: 2010
    ..objective responses in a fraction of patients (10%) including patients who failed other therapies, provided the tumor burden was not excessive. These results provide a proof-of-principle that therapeutic immunity can be elicited...
  27. RNAi-Based Therapy of Hepatocellular Carcinoma
    Kaiyi Li; Fiscal Year: 2007
    ..abstract_text> ..